FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response:

0.5

	Check this box if no longer subject to
)	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Main David				<u>A</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol AQUINOX PHARMACEUTICALS, INC [ AQXP]						[ (Che	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner			
(Last) (First) (Middle) C/O AQUINOX PHARMACEUTICALS INC. 450 - 887 GREAT NORTHERN WAY				3. Date of Earliest Transaction (Month/Day/Year) 03/09/2018					2	X Officer (give title Other (specify below)  President and CEO					
(Street) VANCO		.1 State)	V5T 4T5	4.						Line	) 【 Form fil	idual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			е	Execution Date		Code (Instr.			5. Amoun Securities Beneficia Owned Fo	Form (D) or ollowing (I) (In:	rm: Direct   I or Indirect   I (Instr. 4)   (	7. Nature of ndirect Beneficial Ownership			
							Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)		Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		Code (	Transaction Deri Code (Instr. Sec B) Acq or D of (I		Derivative Expiration		Exercisable and on Date of Securities Underlying Derivative Se (Instr. 3 and 4		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to Buy)	\$16.55	03/09/2018		A		225,000		(1)	03/08/2028	Common Stock	225,000	\$0.00	225,000	D	

## Explanation of Responses:

## Remarks:

/s/ David Main

03/13/2018

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of March 9, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date.